scholarly journals Férfi hormonális fogamzásgátlás: múlt, jelen, jövő

2017 ◽  
Vol 158 (46) ◽  
pp. 1819-1830 ◽  
Author(s):  
Norbert Pásztor ◽  
Borbála Eszter Hegyi ◽  
Attila Badó ◽  
Gábor Németh
Keyword(s):  
Follicle Stimulating Hormone ◽  
Hormone Secretion ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Contraceptive Methods ◽  
Luteinizing Hormone Secretion ◽  
The World ◽  
Effective Contraception ◽  
In The Beginning ◽  
Contraceptive Agent

Abstract: In certain regions of the world the enormous rate of population growth raises economic and public health concerns and widely accessible contraceptive methods would be desired. In contrast, in other countries the use of effective contraception is a question of individual preferences. Today, most of the reliable contraceptive methods are applied by women, while the options for male methods are quite limited. It is well known that significant portion of pregnancies are still unplanned and several data revealed men’s willingness to take part in family planning. Based on these needs, remarkable efforts have been made to develop a suitable hormonal contraceptive agent for men. With the exogenous suppression of follicle stimulating hormone and luteinizing hormone secretion, the inhibition of the testicular testosterone production and the spermatogenesis can be achieved. In the beginning, testosterone-derivatives, or testosterone-progestin combinations were administered, later synthetic androgen agents were developed. Despite of these efforts, unfortunately, there is no safe, widely feasible male hormonal contraception to date, but in the future this goal can be achieved by solving the key hurdles. Orv Hetil. 2017; 158(46): 1819–1830.

COMPARISON OF FOLLICLE-STIMULATING HORMONE AND LUTEINIZING HORMONE SECRETION AFTER ELECTRICAL STIMULATION OF THE PREOPTIC PART OF THE HYPOTHALAMUS IN FEMALE RATS ANAESTHETIZED WITH ETHYL CARBAMATE OR SODIUM PENTOBARBITONE

1978 ◽  
Vol 78 (1) ◽  
pp. 151-152 ◽  
Author(s):  
R. G. DYER ◽  
M. B. TER HAAR ◽  
LINDA C. MAYES
Keyword(s):  
Electrical Stimulation ◽  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Hormone Secretion ◽  
Control Process ◽  
Female Rats ◽  
Female Rat ◽  
Luteinizing Hormone Secretion ◽  
Stimulation Of ◽  
Stimulating Hormone

A.R.C. Institute of Animal Physiology, Babraham, Cambridge, CB2 4AT (Received 17 January 1978) For over 30 years, the method by which the brain regulates the secretion of gonadotrophic hormones has been studied by electrical stimulation of those parts of the central nervous system thought to be implicated in the control process. Much of the work has been performed on the female rat. In this species, anaesthetic doses of sodium pentobarbitone, administered immediately before the pro-oestrous 'critical period', block the preovulatory surge of luteinizing hormone (LH) for 24 h. The same treatment also reduces the early phase of the pro-oestrous secretion of follicle-stimulating hormone (FSH; Daane & Parlow, 1971). Electrical stimulation of the preoptic part of the hypothalamus can overcome this blocking effect and analysis of the optimum parameters required to restore normal secretion of gonadotrophins may give some insight into the endogenous process (e.g. Everett, 1965; Fink & Aiyer, 1974;

scholarly journals Engineering highly multivalent sperm-binding IgG antibodies for potent non-hormonal female contraception

2020 ◽  
Author(s):  
Bhawana Shrestha ◽  
Alison Schaefer ◽  
Jamal Saada ◽  
Zhu Yong ◽  
Timothy M. Jacobs ◽  
...  
Keyword(s):  
Hormonal Contraception ◽  
Human Sperm ◽  
Hormonal Contraceptive ◽  
Medical Applications ◽  
Motile Sperm ◽  
Igg Antibodies ◽  
Contraceptive Methods ◽  
Sperm Binding ◽  
Polymeric Immunoglobulins ◽  
Unique Surface

AbstractMany women risk unintended pregnancy due to dissatisfaction with available hormonal contraceptive methods. This led us to pursue topical sperm-binding monoclonal antibodies as a strategy for safe, non-hormonal contraception. Motivated by the greater agglutination potencies of polymeric immunoglobulins such as IgM and the exceptional bioprocessing ease in manufacturing IgG, we engineered IgGs possessing 6-10 Fabs against a unique surface antigen universally present on human sperm. These highly multivalent IgGs (HM-IgGs) are at least 10- to 16-fold more potent and faster than the parent IgG at agglutinating sperm, while preserving Fc-mediated trapping of individual spermatozoa in mucus. The increased potencies translate to effective (>99.9%) reduction of progressively motile sperm in the sheep vagina using 33 micrograms of the 10 Fab HM-IgG. HM-IgGs produce at comparable yields and possess identical thermal stability to the parent IgG, with greater homogeneity. HM-IgGs represent not only promising biologics for non-hormonal contraception but also a promising platform for generating potent agglutinating mAb for diverse medical applications.

scholarly journals Hormonal Contraception and Diabetes

2012 ◽  
Vol 5 ◽  
pp. CMWH.S9934
Author(s):  
L.F. Pallardo ◽  
A Cano ◽  
I Cristobal ◽  
M.A. Blanco ◽  
M Lozano ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Preconception Care ◽  
Microvascular Complications ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Contraceptive Methods ◽  
Type 2 Dm ◽  
Increased Risk

Women with gestational diabetes mellitus are at increased risk for developing diabetes mellitus (DM), mainly type 2 DM, as well as metabolic syndrome. The presence of subsequent pregnancies increases the risk. In addition, pregnancy in patients with type 1 and type 2 DM also elevates the risk of morbidity and mortality for both mothers and offspring. Thus, all women with pre-existing type 1 or type 2 DM should receive preconception care to optimize glycemic control (HbA1c ≤ 6%). In those cases with macrovascular or microvascular complications, family planning is even more important in order to avoid the risk of aggravation of such complications associated with a new pregnancy. The present review analyzes the metabolic and cardiovascular repercussions of hormone contraception in non-diabetic women as well as in type 1 and type 2 DM patients with and without macrovascular and microvascular complications. Finally, the recommendations pertaining to hormonal contraceptive methods for women with diabetes are summarized.

scholarly journals Update on male hormonal contraception

2019 ◽  
Vol 10 ◽  
pp. 204201881983484 ◽  
Author(s):  
Giulia Gava ◽  
Maria Cristina Meriggiola
Keyword(s):  
Family Planning ◽  
Side Effects ◽  
Contraceptive Method ◽  
Hormonal Contraception ◽  
Active Role ◽  
Hormonal Contraceptives ◽  
Contraceptive Methods ◽  
Men And Women ◽  
Male Contraceptive ◽  
The World

Despite increases in female contraceptive options, 40–45% of pregnancies across the world are still unplanned. While several effective female contraceptive methods have been developed, contraceptive choices for men are still limited to the male condom with its high failure rates and to vasectomies, which are invasive and not reliably reversible. Several studies have demonstrated a great interest among men and women for effective, reversible, and safe male contraceptive methods. Over the years, numerous studies have been performed to develop male hormonal and nonhormonal safe and effective contraceptives. A variety of new molecules are under development as oral or transdermal hormonal contraceptives for men demonstrating few side effects. In our overpopulated world, the development and commercialization of a male contraceptive method that will allow both men and women to take an active role in family planning is mandatory and further research on this topic is required.

Sign in / Sign up

Export Citation Format

Share Document